Margaret A.WinklerMDIndividualAuthorPhil B.FontanarosaMD, Senior EditorsIndividualAuthor
To the Editor: Dr Montaner and
colleagues1 demonstrate that high-level virologic
suppression (HIV RNA level <20 copies/mL) can be achieved in 45%
of patients with CD4 cell counts between 0.20 and 0.60 ×
109/L (200-600/µL) (mean,
0.387×109/L [387/µL]) receiving the
combination of zidovudine, didanosine, and nevirapine, suggesting that
a subgroup of naive patients can be treated with "protease-sparing"
Haubrich R, Richman D. Nevirapine, Didanosine, and Zidovudine for Patients With HIV: The INCAS Trial. JAMA. 1999;281(2):130–131. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-2-jac80019
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: